Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia

BPTH_BP1002_First_Dose_Cohort_Complete_R-R_AML-

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us